Ocular Pain - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Ocular Pain - Pipeline Review, H1 2016', provides an overview of the Ocular Pain pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ocular Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ocular Pain and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Ocular Pain - The report reviews pipeline therapeutics for Ocular Pain by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Ocular Pain therapeutics and enlists all their major and minor projects - The report assesses Ocular Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Ocular Pain Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Ocular Pain - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Ocular Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Ocular Pain Overview 7 Therapeutics Development 8 Pipeline Products for Ocular Pain - Overview 8 Ocular Pain - Therapeutics under Development by Companies 9 Ocular Pain - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Ocular Pain - Products under Development by Companies 13 Ocular Pain - Companies Involved in Therapeutics Development 14 InSite Vision Incorporated 14 Kala Pharmaceuticals, Inc. 15 Ocular Therapeutix, Inc. 16 Reata Pharmaceuticals, Inc. 17 Sylentis S.A.U. 18 Valeant Pharmaceuticals International, Inc. 19 Ocular Pain - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Combination Products 21 Assessment by Target 22 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 30 (bromfenac sodium + dexamethasone acetate) - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 dexamethasone acetate SR - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 difluprednate XR - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 ISV-303 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 ketorolac tromethamine - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 loteprednol etabonate - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 loteprednol etabonate next generation - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 NT-71 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 NT-72 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 omaveloxolone - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 RX-10045 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Small Molecules to Block NaV1.7 Channel for Pain and Pruritus - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 SYL-1001 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Ocular Pain - Recent Pipeline Updates 48 Ocular Pain - Dormant Projects 61 Ocular Pain - Product Development Milestones 62 Featured News & Press Releases 62 Mar 14, 2016: Sylentis Reports Positive Phase II Results With SYL1001 in Treating Ocular Pain Related to Dry Eye Syndrome 62 Jan 11, 2016: Ocular Therapeutix Strengthens Executive Management Team with the Appointment of Highly Regarded Ophthalmologist Jonathan H. Talamo, M.D., as Chief Medical Officer 62 Dec 09, 2015: Ocular Therapeutix Announces FDA Acceptance of NDA Filing for DEXTENZA for the Treatment of Post-Surgical Ocular Pain 63 Oct 14, 2015: Ocular Therapeutix Begins Enrollment in Third Phase 3 Clinical Trial for DEXTENZA for the Treatment of Post-Surgical Ocular Inflammation and Pain 64 Sep 02, 2015: InSite Vision Named in BromSite Patent Lawsuit; Company Believes Lawsuit Is Without Merit 64 Aug 17, 2015: InSite Vision Announces FDA Acceptance of NDA Filing for BromSite 65 May 15, 2015: Ocular Therapeutix Announces Plans to Proceed with an NDA Submission for OTX-DP for Treatment of Post-Surgical Ocular Pain Indication 65 Oct 01, 2013: Ocular Therapeutix Announces Phase 2 Study Results for Sustained Release Dexamethasone 67 Oct 01, 2013: InSite Vision Completes Enrollment of Confirmatory Phase 3 Clinical Study of BromSite for the Reduction of Inflammation and Pain after Cataract Surgery 67 May 09, 2013: InSite Vision Initiates Confirmatory Phase III Clinical Study Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery 68 Appendix 69 Methodology 69 Coverage 69 Secondary Research 69 Primary Research 69 Expert Panel Validation 69 Contact Us 69 Disclaimer 70
List of Tables
Number of Products under Development for Ocular Pain, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 11 Comparative Analysis by Early Stage Development, H1 2016 12 Products under Development by Companies, H1 2016 13 Ocular Pain - Pipeline by InSite Vision Incorporated, H1 2016 14 Ocular Pain - Pipeline by Kala Pharmaceuticals, Inc., H1 2016 15 Ocular Pain - Pipeline by Ocular Therapeutix, Inc., H1 2016 16 Ocular Pain - Pipeline by Reata Pharmaceuticals, Inc., H1 2016 17 Ocular Pain - Pipeline by Sylentis S.A.U., H1 2016 18 Ocular Pain - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2016 19 Assessment by Monotherapy Products, H1 2016 20 Assessment by Combination Products, H1 2016 21 Number of Products by Stage and Target, H1 2016 23 Number of Products by Stage and Mechanism of Action, H1 2016 25 Number of Products by Stage and Route of Administration, H1 2016 27 Number of Products by Stage and Molecule Type, H1 2016 29 Ocular Pain Therapeutics - Recent Pipeline Updates, H1 2016 48 Ocular Pain - Dormant Projects, H1 2016 61
List of Figures
Number of Products under Development for Ocular Pain, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 12 Assessment by Monotherapy Products, H1 2016 20 Number of Products by Top 10 Targets, H1 2016 22 Number of Products by Stage and Top 10 Targets, H1 2016 22 Number of Products by Mechanism of Actions, H1 2016 24 Number of Products by Stage and Mechanism of Actions, H1 2016 24 Number of Products by Routes of Administration, H1 2016 26 Number of Products by Stage and Routes of Administration, H1 2016 26 Number of Products by Molecule Types, H1 2016 28 Number of Products by Stage and Molecule Types, H1 2016 28
Europe industrial air filtration market size is projected to reach USD 1,690.8 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing implementation in various industries such as metal, cement and food & beverages among otRead More...
Global intelligent transportation system (ITS) market is estimated to attain USD 38.68 billion by 2020, as per a new research report by Radiant Insights, Inc. Cost effectiveness along with escalating need for road safety is likely to boost global demRead More...
U.S hairbrush market is estimated to exceed USD 1.2 billion by 2022, as per a new research report by Radiant Insights, Inc. Rising population along with ascending disposable income is expected to drive industry demand. Significant rise in disposableRead More...
Global lignin market size is expected to exceed USD 6 billion by 2022, growing at 4.9% from 2015 to 2022. Rising demand for animal feed and potential as a feedstock substitute to crude oil are expected to drive lignin market demand over the forecastRead More...
Global amino acids market size is anticipated to be valued at USD 35.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in animal feed additive demand owing to regulate metabolism in livestock production owing to growiRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.